{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:22:46Z","timestamp":1772158966735,"version":"3.50.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>We aimed to evaluate the activity of PBTZ169 and pretomanid against non-tuberculous mycobacteriosis (NTM) <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The minimum inhibitory concentrations (MICs) of 11 antibiotics, against slow-growing mycobacteria (SGMs) and rapid-growing mycobacteria (RGMs) were tested using the microplate alamarBlue assay. The <jats:italic>in vivo<\/jats:italic> activities of bedaquiline, clofazimine, moxifloxacin, rifabutin, PBTZ169 and pretomanid against four common NTMs were assessed in murine models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>PBTZ169 and pretomanid had MICs of &amp;gt;32 \u03bcg\/mL against most NTM reference and clinical strains. However, PBTZ169 was bactericidal against <jats:italic>Mycobacterium abscessus<\/jats:italic> (3.33 and 1.49 log10 CFU reductions in the lungs and spleen, respectively) and <jats:italic>Mycobacterium chelonae<\/jats:italic> (2.29 and 2.24 CFU reductions in the lungs and spleen, respectively) in mice, and bacteriostatic against Mycobacterium avium and <jats:italic>Mycobacterium fortuitum<\/jats:italic>. Pretomanid dramatically decreased the CFU counts of <jats:italic>M. abscessus<\/jats:italic> (3.12 and 2.30 log10 CFU reductions in the lungs and spleen, respectively), whereas it showed moderate inhibition of <jats:italic>M. chelonae<\/jats:italic> and <jats:italic>M. fortuitum<\/jats:italic>. Bedaquiline, clofazimine, and moxifloxacin showed good activities against four NTMs <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. Rifabutin did not inhibit <jats:italic>M. avium<\/jats:italic> and <jats:italic>M. abscessus<\/jats:italic> in mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>PBTZ169 appears to be a candidate for treating four common NTM infections. Pretomanid was more active against <jats:italic>M. abscessus<\/jats:italic>, <jats:italic>M. chelonae<\/jats:italic> and <jats:italic>M. fortuitum<\/jats:italic> than against <jats:italic>M. avium<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2023.1115530","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T05:43:10Z","timestamp":1679463790000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB\/c mice models"],"prefix":"10.3389","volume":"13","author":[{"given":"Luyao","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueting","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1128\/AAC.04841-14","article-title":"Characterization of mouse models of mycobacterium avium complex infection and evaluation of drug combinations","volume":"59","author":"Andrejak","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10735-015-9634-3","article-title":"Evidence for the presence of clofazimine and its distribution in the healthy mouse brain","volume":"46","author":"Baijnath","year":"2015","journal-title":"J. Mol. Histol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"11354","DOI":"10.1073\/pnas.1205735109","article-title":"Structural basis of inhibition of mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors","volume":"109","author":"Batt","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007857","article-title":"Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with mycobacterium ulcerans after only 16 doses","volume":"14","author":"Chauffour","year":"2020","journal-title":"PloS Negl. Trop. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/jac\/dkw421","article-title":"Screening of anti-mycobacterial compounds in a naturally infected zebrafish larvae model","volume":"72","author":"Dalton","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220445","article-title":"Drug development challenges in nontuberculous mycobacterial lung disease: TB to the rescue","volume":"219","author":"Dartois","year":"2022","journal-title":"J. Exp. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic outcome of interventions against mycobacterium avium complex pulmonary disease: A systematic review","volume":"153","author":"Diel","year":"2018","journal-title":"Chest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.5588\/ijtld.15.0807","article-title":"Mortality among patients with pulmonary non-tuberculous mycobacteria disease","volume":"20","author":"Fleshner","year":"2016","journal-title":"Int. J. Tuberc Lung Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/MCP.0000000000000764","article-title":"Atypical mycobacterial infections - management and when to treat","volume":"27","author":"Gill","year":"2021","journal-title":"Curr. Opin. Pulm Med."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004022","article-title":"In vivo activity of the benzothiazinones PBTZ169 and BTZ043 against nocardia brasiliensis","volume":"9","author":"Gonzalez-Martinez","year":"2015","journal-title":"PloS Negl. Trop. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1093\/jac\/dkv054","article-title":"Bactericidal mode of action of bedaquiline","volume":"70","author":"Hards","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/s41467-022-28638-5","article-title":"Rough and smooth variants of mycobacterium abscessus are differentially controlled by host immunity during chronic infection of adult zebrafish","volume":"13","author":"Kam","year":"2022","journal-title":"Nat. Commun."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","article-title":"Pretomanid: First approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1038\/ncomms4369","article-title":"Delayed bactericidal response of mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism","volume":"5","author":"Koul","year":"2014","journal-title":"Nat. Commun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1016\/S1473-3099(21)00586-7","article-title":"Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases","volume":"22","author":"Lange","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/22221751.2019.1710090","article-title":"The potassium transporter KdpA affects persister formation by regulating ATP levels in mycobacterium marinum","volume":"9","author":"Liu","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"B19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/emmm.201303575","article-title":"Towards a new combination therapy for tuberculosis with next generation benzothiazinones","volume":"6","author":"Makarov","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1093\/cid\/ciaa1267","article-title":"Reduction in expected survival associated with nontuberculous mycobacterial pulmonary disease","volume":"72","author":"Mourad","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2021.126887","article-title":"Growth medium and nitric oxide alter mycobacterium abscessus morphotype and virulence","volume":"253","author":"Nandanwar","year":"2021","journal-title":"Microbiol. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1513\/AnnalsATS.201610-800OC","article-title":"Mortality after respiratory isolation of nontuberculous mycobacteria. a comparison of patients who did and did not meet disease criteria","volume":"14","author":"Novosad","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.micinf.2004.11.006","article-title":"Murine infection model for mycobacterium fortuitum","volume":"7","author":"Parti","year":"2005","journal-title":"Microbes Infect."},{"key":"B24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3201\/eid2203.151643","article-title":"Leveraging advances in tuberculosis diagnosis and treatment to address nontuberculous mycobacterial disease","volume":"22","author":"Raju","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"11945","DOI":"10.1073\/pnas.0711697105","article-title":"The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating mycobacterium tuberculosis","volume":"105","author":"Rao","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1099\/00221287-147-4-1017","article-title":"Intracellular pH regulation by mycobacterium smegmatis and mycobacterium bovis BCG","volume":"147","author":"Rao","year":"2001","journal-title":"Microbiol. (Reading)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00303","article-title":"The rise of non-tuberculosis mycobacterial lung disease","volume":"11","author":"Ratnatunga","year":"2020","journal-title":"Front. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1128\/AAC.32.3.400","article-title":"Susceptibilities of transparent, opaque, and rough colonial variants of mycobacterium avium complex to various fatty acids","volume":"32","author":"Saito","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1314","DOI":"10.1128\/AAC.01314-18","article-title":"In vitro activity of PBTZ169 against multiple mycobacterium species","volume":"62","author":"Shi","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2021.102081","article-title":"Inhalable particles containing isoniazid and rifabutin as adjunct therapy for safe, efficacious and relapse-free cure of experimental animal tuberculosis in one month","volume":"128","author":"Singh","year":"2021","journal-title":"Tuberculosis (Edinb)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e02155","DOI":"10.1128\/AAC.02155-18","article-title":"In vitro and In vivo activities of the riminophenazine TBI-166 against mycobacterium tuberculosis","volume":"63","author":"Xu","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2147\/IDR.S240716","article-title":"Comparison of in vitro susceptibility of mycobacteria against PA-824 to identify key residues of ddn, the deazoflavin-dependent nitroreductase from mycobacterium tuberculosis","volume":"13","author":"Zhang","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02496-18","article-title":"Identifying regimens containing TBI-166, a new drug candidate against mycobacterium tuberculosis in vitro and In vivo","volume":"63","author":"Zhang","year":"2019","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1115530\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T05:32:53Z","timestamp":1680499973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1115530\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":33,"alternative-id":["10.3389\/fcimb.2023.1115530"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1115530","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]},"article-number":"1115530"}}